[
  {
    "ts": "2025-10-02T15:37:00+00:00",
    "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
    "summary": "Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.",
    "url": "https://www.fool.com/investing/2025/10/02/should-you-buy-the-3-highest-paying-dividend-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "cb652939-fd4f-383e-aad6-673b59c30d12",
      "content": {
        "id": "cb652939-fd4f-383e-aad6-673b59c30d12",
        "contentType": "STORY",
        "title": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
        "description": "",
        "summary": "Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.",
        "pubDate": "2025-10-02T15:37:00Z",
        "displayTime": "2025-10-02T15:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/2f65e2830dca4052cb21e85ab7c9517c",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Someone celebrating what is showing on her phone.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4EC5ezOdE6sFHWbKVGTLmA--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/2f65e2830dca4052cb21e85ab7c9517c.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1Kw7cf380I9OHLKoOOgNEg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/2f65e2830dca4052cb21e85ab7c9517c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/02/should-you-buy-the-3-highest-paying-dividend-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-3-highest-paying-dividend-153700994.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VZ"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T15:15:00+00:00",
    "headline": "Can Novo Nordisk's Restructuring Program Drive its Return to Growth?",
    "summary": "NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.",
    "url": "https://finance.yahoo.com/news/novo-nordisks-restructuring-program-drive-151500942.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1e925887-82c4-3629-8fa0-d36689e08fad",
      "content": {
        "id": "1e925887-82c4-3629-8fa0-d36689e08fad",
        "contentType": "STORY",
        "title": "Can Novo Nordisk's Restructuring Program Drive its Return to Growth?",
        "description": "",
        "summary": "NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.",
        "pubDate": "2025-10-02T15:15:00Z",
        "displayTime": "2025-10-02T15:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OpV4giEb4QjgN71LPYFzIw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QcLiFahMpkHBfBp4mOYpEQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-restructuring-program-drive-151500942.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-restructuring-program-drive-151500942.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T14:32:00+00:00",
    "headline": "Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?",
    "summary": "Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.",
    "url": "https://finance.yahoo.com/news/could-mrnas-upcoming-product-launches-143200209.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ecde06e1-e384-3771-a3b9-3eb885f91bcf",
      "content": {
        "id": "ecde06e1-e384-3771-a3b9-3eb885f91bcf",
        "contentType": "STORY",
        "title": "Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?",
        "description": "",
        "summary": "Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.",
        "pubDate": "2025-10-02T14:32:00Z",
        "displayTime": "2025-10-02T14:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9e8d93e17a792e7de990e3344e61fa6a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RbEQ9ffI_C.cs8maxLm5aA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9e8d93e17a792e7de990e3344e61fa6a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7WrOhRUUvHYeo9ae0mpZAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9e8d93e17a792e7de990e3344e61fa6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/could-mrnas-upcoming-product-launches-143200209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/could-mrnas-upcoming-product-launches-143200209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T14:04:00+00:00",
    "headline": "LEXX: Biodistribution Study Results",
    "summary": "By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this",
    "url": "https://finance.yahoo.com/news/lexx-biodistribution-study-results-140400819.html",
    "source": "Zacks Small Cap Research",
    "provider": "yfinance",
    "raw": {
      "id": "503b318a-ca72-3da8-b8e3-7aefcb41b18f",
      "content": {
        "id": "503b318a-ca72-3da8-b8e3-7aefcb41b18f",
        "contentType": "STORY",
        "title": "LEXX: Biodistribution Study Results",
        "description": "",
        "summary": "By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this",
        "pubDate": "2025-10-02T14:04:00Z",
        "displayTime": "2025-10-02T14:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/scr.zacks.com/df2c5c680fd677b4b6561f370ad4449a",
          "originalWidth": 1348,
          "originalHeight": 1186,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y2xJ4ZaG.uI6CK9iQoZeww--~B/aD0xMTg2O3c9MTM0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/scr.zacks.com/df2c5c680fd677b4b6561f370ad4449a.cf.webp",
              "width": 1348,
              "height": 1186,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hmzPkN1MjblhsiWhC67bYQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/df2c5c680fd677b4b6561f370ad4449a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks Small Cap Research",
          "url": "http://scr.zacks.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lexx-biodistribution-study-results-140400819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lexx-biodistribution-study-results-140400819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LEXX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "SEPN"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "ZEAL.CO"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T13:45:00+00:00",
    "headline": "Merck Manuals Shares What Patients Need to Know About COPD",
    "summary": "Chronic obstructive pulmonary disease (COPD) is a leading cause of death in many smokers and former smokers.",
    "url": "https://finance.yahoo.com/news/merck-manuals-shares-patients-know-134500823.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "fc7ca157-1ff0-397c-bd19-1d94a1d31bc7",
      "content": {
        "id": "fc7ca157-1ff0-397c-bd19-1d94a1d31bc7",
        "contentType": "STORY",
        "title": "Merck Manuals Shares What Patients Need to Know About COPD",
        "description": "",
        "summary": "Chronic obstructive pulmonary disease (COPD) is a leading cause of death in many smokers and former smokers.",
        "pubDate": "2025-10-02T13:45:00Z",
        "displayTime": "2025-10-02T13:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/889d609ff9d451cab9a38be2830ef40a",
          "originalWidth": 400,
          "originalHeight": 73,
          "caption": "MerckManuals.com (PRNewsfoto/MerckManuals.com)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sIEFgE_NceQBPreM4Qjoig--~B/aD03Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/889d609ff9d451cab9a38be2830ef40a.cf.webp",
              "width": 400,
              "height": 73,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jUUVqlEMp2qkitLq4gxznw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/889d609ff9d451cab9a38be2830ef40a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-manuals-shares-patients-know-134500823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-manuals-shares-patients-know-134500823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T13:30:03+00:00",
    "headline": "Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?",
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "url": "https://finance.yahoo.com/news/worth-investing-merck-mrk-based-133003532.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2cd398d6-78aa-3592-a18e-be1461071ea4",
      "content": {
        "id": "2cd398d6-78aa-3592-a18e-be1461071ea4",
        "contentType": "STORY",
        "title": "Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?",
        "description": "",
        "summary": "According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
        "pubDate": "2025-10-02T13:30:03Z",
        "displayTime": "2025-10-02T13:30:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uV6mPOIlsfK8Kl7nmlunJw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sc4z8_.3guA7NR27rd8O3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/worth-investing-merck-mrk-based-133003532.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/worth-investing-merck-mrk-based-133003532.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T13:00:05+00:00",
    "headline": "Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?",
    "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finance.yahoo.com/news/most-watched-stock-merck-co-130005830.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0a254f4b-b1fc-3865-8807-6846aae95c8e",
      "content": {
        "id": "0a254f4b-b1fc-3865-8807-6846aae95c8e",
        "contentType": "STORY",
        "title": "Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?",
        "description": "",
        "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "pubDate": "2025-10-02T13:00:05Z",
        "displayTime": "2025-10-02T13:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85",
          "originalWidth": 900,
          "originalHeight": 636,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eN0EvS2DQjGO_6Aa8hYV4w--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85.cf.webp",
              "width": 900,
              "height": 636,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IXPNK2bXbxtvuH6_.DBDbA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/most-watched-stock-merck-co-130005830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/most-watched-stock-merck-co-130005830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T12:00:00+00:00",
    "headline": "HEALTH CANADA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-release Injectable Suspension) from Merck Animal Health",
    "summary": "Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), announced Health Canada's approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly injectable product.",
    "url": "https://finance.yahoo.com/news/health-canada-approves-bravecto-quantum-120000383.html",
    "source": "CNW Group",
    "provider": "yfinance",
    "raw": {
      "id": "8def103f-399f-35c0-8d84-68a5a0b5d865",
      "content": {
        "id": "8def103f-399f-35c0-8d84-68a5a0b5d865",
        "contentType": "STORY",
        "title": "HEALTH CANADA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-release Injectable Suspension) from Merck Animal Health",
        "description": "",
        "summary": "Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), announced Health Canada's approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly injectable product.",
        "pubDate": "2025-10-02T12:00:00Z",
        "displayTime": "2025-10-02T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cnwgroup.com/132fd00419e99de459ec13002b3bd88c",
          "originalWidth": 400,
          "originalHeight": 199,
          "caption": "https://www.merck.ca/en/ (PRNewsfoto/Merck)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A_PLut7jcLKoM4FD9NaN.A--~B/aD0xOTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/132fd00419e99de459ec13002b3bd88c.cf.webp",
              "width": 400,
              "height": 199,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r66ERUkgIlqTBnOF7upJXA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/132fd00419e99de459ec13002b3bd88c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CNW Group",
          "url": "http://www.newswire.ca/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/health-canada-approves-bravecto-quantum-120000383.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/health-canada-approves-bravecto-quantum-120000383.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T07:28:32+00:00",
    "headline": "Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?",
    "summary": "This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.",
    "url": "https://www.pharmavoice.com/news/merck-keytruda-subcutaneous-cancer-sales-drug-delivery/761607/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "9d8e7de8-49b1-3b2e-a01e-3cc2c40351af",
      "content": {
        "id": "9d8e7de8-49b1-3b2e-a01e-3cc2c40351af",
        "contentType": "STORY",
        "title": "Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?",
        "description": "",
        "summary": "This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.",
        "pubDate": "2025-10-02T07:28:32Z",
        "displayTime": "2025-10-02T07:28:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/1af7ccba733015fb9e825e2056272a49",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Vu15mL9ssGwrVQ0URUOig--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/1af7ccba733015fb9e825e2056272a49.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JOqN7_Cug1ASKy6nVxhlKw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/1af7ccba733015fb9e825e2056272a49.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/merck-keytruda-subcutaneous-cancer-sales-drug-delivery/761607/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/half-merck-sales-jeopardy-keytruda-072832968.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T06:55:38+00:00",
    "headline": "Merck & Co (MRK) Announced Positive Results From Phase 3 HYPERION Trial of WINREVAIR",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 30, Merck & Co., Inc. (NYSE:MRK) announced positive results from its Phase 3 HYPERION trial of WINREVAIR in adults recently diagnosed with pulmonary arterial hypertension. The trial included patients classified as functional class 2 or […]",
    "url": "https://finance.yahoo.com/news/merck-co-mrk-announced-positive-065538021.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "641e55f0-d927-34df-8914-1e38b9212ec5",
      "content": {
        "id": "641e55f0-d927-34df-8914-1e38b9212ec5",
        "contentType": "STORY",
        "title": "Merck & Co (MRK) Announced Positive Results From Phase 3 HYPERION Trial of WINREVAIR",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 30, Merck & Co., Inc. (NYSE:MRK) announced positive results from its Phase 3 HYPERION trial of WINREVAIR in adults recently diagnosed with pulmonary arterial hypertension. The trial included patients classified as functional class 2 or […]",
        "pubDate": "2025-10-02T06:55:38Z",
        "displayTime": "2025-10-02T06:55:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IzRhrl6IP..dz_8NtaA67g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C.KM1e7Q4T5mCkqt60S1Yg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-announced-positive-065538021.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-announced-positive-065538021.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-02T05:35:40+00:00",
    "headline": "Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) and increased its price target from $75 to $90. The firm attributed the higher target to favorable financial forecasts and solid earnings results for the first half of 2025. Benchmark’s […]",
    "url": "https://finance.yahoo.com/news/benchmark-sees-more-upside-halozyme-053540281.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "b1b86e73-d9cb-3094-a6d1-1102f38b0f22",
      "content": {
        "id": "b1b86e73-d9cb-3094-a6d1-1102f38b0f22",
        "contentType": "STORY",
        "title": "Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target",
        "description": "",
        "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the best biotech stocks to buy. On September 24, Benchmark maintained its Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) and increased its price target from $75 to $90. The firm attributed the higher target to favorable financial forecasts and solid earnings results for the first half of 2025. Benchmark’s […]",
        "pubDate": "2025-10-02T05:35:40Z",
        "displayTime": "2025-10-02T05:35:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/73a093020100e8a32a1b4f97a4b8ba9b",
          "originalWidth": 512,
          "originalHeight": 111,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QBPPVSV6JkivwVrYTJmW1w--~B/aD0xMTE7dz01MTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/73a093020100e8a32a1b4f97a4b8ba9b.cf.webp",
              "width": 512,
              "height": 111,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lQ2buIKuqivVd0O2X1ViuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/73a093020100e8a32a1b4f97a4b8ba9b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/benchmark-sees-more-upside-halozyme-053540281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/benchmark-sees-more-upside-halozyme-053540281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HALO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "196170.KQ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]